Journal article
Advancing therapeutics in small-cell lung cancer
Nature cancer, Vol.6(6), pp.938-953
06/01/2025
DOI: 10.1038/s43018-025-00996-1
PMID: 40523990
Abstract
Small-cell lung cancer (SCLC) accounts for 10-15% of lung cancers and is characterized by early metastasis, treatment resistance and rapid progression. Treatment advancements have been stagnant for decades, with chemotherapy as the mainstay and immune checkpoint inhibitors offering only modest survival extensions. However, new insights into tumor heterogeneity and recent practice-changing observations such as the identification of targetable cell surface proteins could effectively transform SCLC therapy. In this Review, we highlight key advances in SCLC biology, therapeutic innovation and biomarker development. Finally, we discuss the role of reverse translation in optimizing treatments, approaches to overcoming resistance and ensuring equitable access to care.
Details
- Title: Subtitle
- Advancing therapeutics in small-cell lung cancer
- Creators
- Anish Thomas - National Institutes of HealthChirayu Mohindroo - National Institutes of HealthGiuseppe Giaccone - Cornell University
- Resource Type
- Journal article
- Publication Details
- Nature cancer, Vol.6(6), pp.938-953
- DOI
- 10.1038/s43018-025-00996-1
- PMID
- 40523990
- NLM abbreviation
- Nat Cancer
- ISSN
- 2662-1347
- eISSN
- 2662-1347
- Grant note
- ZIA BC 011793 / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- Language
- English
- Date published
- 06/01/2025
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985178656602771
Metrics
2 Record Views